Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis.
Lutt
Joseph R
JR
Pisculli
Mary L
ML
Weinblatt
Michael E
ME
Deodhar
Atul
A
Winthrop
Kevin L
KL
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000917:Antibody Formation / Q000187:drug effects; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000187:drug effects; D005260:Female; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D007155:Immunologic Factors / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000276:immunology*; D009162:Mycobacterium avium / Q000302:isolation & purification; D019909:Mycobacterium kansasii / Q000302:isolation & purification; D009220:Myositis / Q000188:drug therapy* / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D000069283:Rituximab; D011241:Prednisone